Viracta Therapeutics, Inc.
(NASDAQ : VIRX)

( )
VIRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.31%324.210.0%$4670.09m
BNTXBioNTech SE -1.06%247.680.0%$730.32m
NVAXNovavax, Inc. -4.59%161.9579.4%$715.24m
AMGNAmgen, Inc. 0.51%207.841.4%$575.65m
SNSSSunesis Pharmaceuticals, Inc. -7.57%6.470.7%$452.28m
GILDGilead Sciences, Inc. -0.76%67.631.0%$426.45m
REGNRegeneron Pharmaceuticals, Inc. -0.43%553.242.7%$408.99m
ILMNIllumina, Inc. 0.45%409.933.5%$392.87m
CCXIChemoCentryx, Inc. -7.04%34.472.9%$387.64m
XLRNAcceleron Pharma, Inc. 0.50%172.945.3%$345.45m
VRTXVertex Pharmaceuticals, Inc. -0.07%181.771.9%$259.59m
BIIBBiogen, Inc. -1.43%281.191.7%$243.39m
OCGNOcugen, Inc. -13.83%8.660.0%$178.37m
XENEXenon Pharmaceuticals, Inc. 2.12%33.660.4%$178.19m
JSPRJasper Therapeutics, Inc. 31.57%16.420.0%$158.53m

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.